Baseline clinical and pathological characteristics of patients included in the study
| Part I | Part II | Part III | ||||||
| (n=16) | (n=12) | (n=14) | ||||||
| I-1 | I-2 | I-3 | I-4 | II-1 | II-2 | III-1 | III-2 | |
| 1×1011 vp | 1×1012 vp | 3.3×1012 vp | 1×1013 vp | 3.3×1012 vp | 1×1013vp | 3.3×1012 vp | 1×1013vp | |
| (n=3) | (n=4) | (n=3) | (n=6) | (n=6) | (n=6) | (n=8) | (n=6) | |
| Characteristics | ||||||||
| Median age, years (range) | 66 (37–77) | 60 (35–75) | 66 (49–86) | |||||
| 67 (60–69) | 70 (67–77) | 72 (64–75) | 54 (37–63) | 61 (46–75) | 59 (35–73) | 64 (49–86) | 68 (51–77) | |
| Sex (male/female) | 2/1 | 3/1 | 2/1 | 5/1 | 3/3 | 4/2 | 3/5 | 2/4 |
| ECOG | ||||||||
| 0 | 1 | 2 | 1 | 1 | 2 | 2 | 2 | 2 |
| 1 | 2 | 2 | 2 | 5 | 4 | 4 | 4 | 4 |
| Primary disease | ||||||||
| Colorectal—stage IV | 3 | 4 | 3 | 5 | 0 | 0 | 0 | 0 |
| Head and neck | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Pancreas–stage III | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 0 |
| Pancreas–stage IV | 0 | 0 | 0 | 0 | 5 | 5 | 6 | 6 |
| Site of metastatic disease | ||||||||
| Liver (only) | 1 | 2 | 0 | 1 | 4 | 3 | 2 | 4 |
| Lung (only) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Liver and lung (and other) | 1 | 0 | 1 | 5 | 1 | 1 | 1 | 0 |
| Liver (and other) | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Other | 1 | 2 | 2 | 0 | 0 | 0 | 2 | 0 |
| Previous antineoplastic treatment (yes/no) | ||||||||
| 3/0 | 4/0 | 3/0 | 6/0 | 2/4 | 2/4 | 0/8 | 2/4 | |
ECOG, Eastern Cooperative Oncology Group Performance Status Scale; vp, viral particles .